Grifols SA
MAD:GRF

Watchlist Manager
Grifols SA Logo
Grifols SA
MAD:GRF
Watchlist
Price: 9.24 EUR 0.41%
Market Cap: 6.3B EUR
Have any thoughts about
Grifols SA?
Write Note

P/E
Price to Earnings

43.6
Current
31.1
Median
22.1
Industry
Higher than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
43.6
=
Market Cap
6.3B EUR
/
Net Income
143.9m EUR
All Countries
Close
Market Cap P/E
ES
Grifols SA
MAD:GRF
6.3B EUR 43.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -181 287
US
Abbvie Inc
NYSE:ABBV
315.2B USD 62
US
Amgen Inc
NASDAQ:AMGN
141.9B USD 33.5
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD 923.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD -217.7
US
Epizyme Inc
F:EPE
94.1B EUR -471.3
AU
CSL Ltd
ASX:CSL
135.7B AUD 32.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 16.9
US
Seagen Inc
F:SGT
39.3B EUR -54.6
NL
argenx SE
XBRU:ARGX
36B EUR -135.3
Earnings Growth P/E to Growth
ES
Grifols SA
MAD:GRF
Average P/E: 185.3
43.6
1 304%
0
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 287 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
923.6
77%
12
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -217.7
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.3 N/A N/A
AU
CSL Ltd
ASX:CSL
32.1
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.3 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
14
2-Years Forward
P/E
9.4
3-Years Forward
P/E
7.6

See Also

Discover More